10578-75-3

Usage

Uses

Used in Pharmaceutical Industry:
2-(Benzyloxy)-1-ethanamine hydrochloride is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its ability to form single and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles makes it a valuable component in the synthesis of anti-HIV-1 agents.
Used in Antiviral Applications:
In the field of antiviral research, 2-(Benzyloxy)-1-ethanamine hydrochloride plays a crucial role in the synthesis of compounds with anti-HIV-1 activities. These synthesized compounds can potentially help in the development of new treatments and therapies for HIV-1 infections.
Used in Drug Delivery Systems:
Similar to gallotannin, 2-(Benzyloxy)-1-ethanamine hydrochloride can also be employed in the development of novel drug delivery systems. These systems aim to improve the bioavailability, delivery, and therapeutic outcomes of the synthesized compounds, making them more effective in treating various medical conditions.

InChI:InChI=1/C9H13NO.ClH/c10-6-7-11-8-9-4-2-1-3-5-9;/h1-5H,6-8,10H2;1H

Upstream product

• 2002-24-6 2-amino-ethanol hydrochloride 
• 100-44-7 benzyl chloride 
• 634925-24-9 tert-butyl (2-(benzyloxy)ethyl)carbamate 

Downstream Products

• 298712-73-9 N¹,N²⁴-bis[2-(benzyloxy)ethyl]-1,24-tetracosanediamide 
• 298712-66-0 N-[2-(benzyloxy)ethyl]hexadecylamide 
• 155769-05-4 2-chloro-N-[2-(phenylmethoxy)ethyl]adenosine 
• 1207634-76-1 N-[2-(benzyloxy)ethyl]-1H-imidazole-1-carboxamide 
• 78407-19-9 [(2-isocyanatoethoxy)methyl]benzene 
• 1093643-63-0 N-(2-benzyloxy-ethyl)-2-(1-hydroxy-1,3-dihydro-benzo[c][1,2]oxaborol-7-yloxy)-acetamide 
• 634925-25-0 N-[2-(benzyloxy)ethyl]-2-chloro-5,6-dimethyl-3-nitropyridin-4-amine 
• 298712-67-1 N-[2-(benzyloxy)ethyl]hexadecylamine 
• 350689-56-4 methyl N-[2-(benzyloxy)ethyl]-N-[7-(F-octyl)heptyl]-11-carboxamidoundecanoate 
• 350689-58-6 N-[2-(benzyloxy)ethyl]-7-(F-octyl)heptylamine 
• 350689-55-3 N-[2-(benzyloxy)ethyl]-7-(F-octyl)heptanamide 

Relevant academic research and scientific papers

A method for the production of primary amines

The invention relates to the field of chemical industry and particularly relates to a method for preparing primary amine by using the raw materials including halogenated hydrocarbon (or hydrocarbon alcohol sulfonate) and ammonia water (or formamide). The method comprises the following three steps: (1) imidization: 3,4-diarylfuran-2,5-diketone (I) reacts with ammonia (or formamide) and the like to obtain 3,4-diaryl-1H-pyrrole-2,5-diketone (II); (2) N-hydrocarbylation: 3,4-diaryl-1H-pyrrole-2,5-diketone (II) generates an N-hydrocarbylation reaction with halogenated hydrocarbon (or hydrocarbon alcohol sulfonate) in the presence of alkali to obtain N-hydrocarbyl-3,4-diaryl-1H-pyrrole-2,5-diketone (III); and (3) hydrolysis: N-hydrocarbyl-3,4-diaryl-1H-pyrrole-2,5-diketone (III) is subjected to alkali hydrolysis to obtain primary amine and the generated 2,3-diaryl maleate is subjected to acid treatment and automatic ring closing to form 3,4-diaryl furan-2,5-diketone (I) which is subjected to imidization and directly applied to the N-hydrocarbylation reaction. The method provided by the invention has the characteristics that the 3,4-diaryl furan-2,5-diketone can be circularly used at a high recovery rate, the molar ratio of the raw materials is low, and the yield of the product primary amine is high.

IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR

Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-KB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.

1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF

A 1,5-naphthyridine derivative represented by Formula [1] (in which R1, R2, R3, R4 and R5 represent a hydrogen atom, -L-Z (in which Z represents a non-aromatic heterocyclic group or the like; and L re

Ether substituted imidazopyridines

Imidazopyridine compounds that contain an ether or thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.

Dipeptide inhibitors of protein farnesyltransferase

The present invention provides compounds having the structure represented by formula (I). Also provided is a method of treating cancer, restenosis, atherosclerosis, or psoriasis or preventing restenosis, and a pharmaceutical composition comprising a compo

Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity

Galactosylceramide (GalCer) is an alternative receptor allowing HIV-1 entry into CD4(-)/GalCer(+) cells. This glycosphingolipid recognizes the V3 loop of HIV gp120, which plays a key role in the fusion of the HIV envelope and cellular membrane. To inhibit HIV uptake and infection, we designed and synthesized analogs of GalCer. These amphiphiles and bolaamphiphiles consist of single and double hydrocarbon and/or fluorocarbon chain β-linked to galactose and galactosamine. They derive from serine (GalSer), cysteine (GalCys), and ethanolamine (GalAE). The anti-HIV activity and cytotoxicity of these galactolipids were evaluated in vitro on CEM-SS (a CD4(+) cell line), HT-29, a CD4(-) cell line expressing high levels of GalCer receptor, and/or HT29 genetically modified to express CD4. GalSer and GalAE derivatives, tested in aqueous medium or as part of liposome preparation, showed moderate anti-HIV-1 activities (IC50 in the 20-220 μM range), whereas none of the GalCys derivatives was found to be active. Moreover, only some of these anti-HIV active analogs inhibited the binding of [3H]suramin (a polysulfonyl compound which displays a high affinity for the V3 loop) to SPC3, a synthetic peptide which contains the conserved GPGRAF region of the V3 loop. Our results most likely indicate that the neutralization of the virion through masking of this conserved V3 loop region is not the only mechanism involved in the HIV-1 antiviral activity of our GalCer analogs. Copyright (C) 2000 Elsevier Science Ltd.